Jun 22, 2026 08:02AM
Jun 22, 2026 08:00AM
Jun 3, 2026 08:03AM
Jun 3, 2026 08:00AM
May 12, 2026 04:02PM
May 12, 2026 04:02PM
May 4, 2026 08:00AM Kyverna Therapeutics names Nadia Dac as chief commercial officer
May 4, 2026 08:00AM
Apr 22, 2026 09:38AM
Apr 22, 2026 07:03AM
Apr 21, 2026 06:45PM
Apr 20, 2026 08:02AM
Apr 20, 2026 08:00AM
Apr 9, 2026 08:00AM Kyverna Therapeutics to Host Conference Call on New Data Across Neuroimmunology Franchise at AAN 2026
Mar 26, 2026 04:02PM
Mar 5, 2026 04:21PM
Mar 5, 2026 04:21PM
Jan 12, 2026 08:09AM
Jan 12, 2026 08:00AM
Dec 15, 2025 06:30AM
Dec 15, 2025 06:30AM Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome
Nov 12, 2025 04:05PM
Oct 29, 2025 06:30AM
Oct 29, 2025 06:30AM
Sep 15, 2025 01:02PM
Sep 15, 2025 01:02PM
Aug 28, 2025 08:00AM
Aug 28, 2025 08:00AM Kyverna shares Phase 3 trial design for myasthenia gravis treatment
Aug 28, 2025 08:00AM
Aug 28, 2025 08:00AM
Aug 20, 2025 05:06AM
Aug 12, 2025 04:02PM
Jul 29, 2025 08:30AM
May 13, 2025 04:02PM
Apr 3, 2025 06:46AM Kyverna Therapeutics Inc (KYTX) PT Lowered to $4 at H.C. Wainwright
Mar 31, 2025 08:59AM
Mar 27, 2025 04:02PM
Mar 24, 2025 09:13AM
Mar 17, 2025 03:01PM
Mar 13, 2025 06:21PM
Jan 13, 2025 07:30AM
Nov 13, 2024 04:14PM Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
Aug 15, 2024 06:41AM
Aug 12, 2024 04:08PM
Aug 12, 2024 04:05PM
Aug 12, 2024 04:05PM
Jul 16, 2024 10:54AM
Jul 15, 2024 04:05PM
Jun 20, 2024 08:55AM Kyverna Therapeutics (KYTX) Receives U.S. FDA IND Clearance for KYV-101
Jun 20, 2024 08:55AM

325,591 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All